

QUARTERLY ACTIVITIES & CASHFLOW REPORT QUARTER ENDED 30 SEPTEMBER 2026

Adelaide, Australia, 30 October 2026: Australian medical technology company Clever Culture Systems Ltd (ASX: CC5) (CCS or the **Company**), a leader in microbiology automation using artificial intelligence, is pleased to release its Appendix 4C – Quarterly Cashflow report and business update for the quarter ended 30 September 2026 (the **Quarter**). All financial results are in Australian dollars and are unaudited.

Key Highlights

- **3 APAS® sales completed and invoiced in Q1 FY27 with Novo and AstraZeneca**, representing momentum of the “Expand” sales phase with existing global pharmaceutical customers
- **H1 FY27 sales and new evaluations expected to reach 8 units**, underpinning ambitions of a step-change increase in FY27 sales performance
- **PSC Biotech appointed Sales Agent for North America and Singapore**, extending CCS’s market reach into regional and single-site pharmaceutical manufacturers
- **Sales pipeline underpinned by existing global pharmaceutical customers**, strengthened with expectations of adding 1 new global pharmaceutical customer in H1 FY27
- **Cash:** 30 September 2026 cash balance of \$1.4 million, and \$3.9 million in expected¹/committed cash inflows over the next two quarters

Regarding the Quarter, Brent Barnes, CEO and Managing Director said:

“Our Q1 FY27 sales delivered a sound start to FY27, with three APAS® Independence sales completed and invoiced within our global pharmaceutical customer base. We expect an acceleration of sales to be achieved for the first half of FY27, converting evaluations into purchases and broader APAS® deployments across our existing global pharmaceutical customers’ manufacturing networks. The appointment of PSC Biotech adds a complementary sales channel to accelerate our reach into the US and other key markets. These developments underpin our confidence in the growth opportunity for APAS® Independence in FY27 and beyond.”

Sales delivery and execution

Sales Progress Summary – Quarterly sales progress on track for step change increase in sales for FY27

	Q1 FY27	Q4 FY26	Q1 FY26
Global Pharma Customers	8	8	5
Instruments Installed Base²	37	34	26
New Orders Received in the Quarter³	2	3	1
Instruments under evaluation	3	3	1

Sales focus on global pharmaceutical manufacturers underpins sales for FY27

The Financial Year (FY) 2027 has started positively with three APAS® Independence sales completed, with instruments installed and invoiced, during the Quarter. This included two sales to Novo Nordisk in Europe and one sale to AstraZeneca in the United States.

¹ Expected receipts include four advanced sales opportunities and an installation that are expected to advance to firm contracts in the quarter ended 31 December 2026 (refer ASX Announcement 28 October 2026).

² APAS® instruments have been fully purchased and installed (Pharma & Clinical), excludes instruments under evaluation with a return option

³ All orders received and committed within the Quarter (Pharma & Clinical). The 1 sale to AstraZeneca was delivered and invoiced in Q1FY27 but received in Q4 FY26

Importantly, the contract for the sale of the two instruments to Novo Nordisk included CCS' development of an advanced integration solution for Novo Nordisk's global Laboratory Information Management Solution (LIMS). This development is an important enabling step to support any further expansion of the APAS® technology across additional Novo Nordisk global manufacturing sites. The principal aspects of the LIMS connectivity have now been successfully completed, substantially derisking the technical risk of the development. The integration features are now being further enhanced with development expected to be substantially completed in early calendar year 2027.

FY26 delivered a focus on executing sales to new global pharmaceutical manufacturers and to actively support them through an evaluation process for the APAS® technology. This has established a large sales opportunity of approximately 100 potential future instrument sales across this customer segment. It is expected that three of these customers will have completed their evaluations during the first half of FY27, with APAS® performance meeting expectations, and progressing to a technology roll out phase within their organisations. Each customer will progress at different rates, with different corporate strategies and processes for site procurement globally.

CCS expects to finalise a contract with a new Top-20 global pharmaceutical company to commence a paid evaluation of APAS® Independence in Q2 FY27. Evaluations assess the analytical performance of the instrument and suitability for potential expansion across a customer's global drug manufacturing network, consistent with the Company's 'land and expand' sales strategy. An expanding customer base provides a growing foundation for potential multi-site deployments.

PSC Biotech adds a complementary sales channel alongside CCS's direct "Land & Expand" strategy

In October, the Company appointed PSC Biotech as the sole Sales Agent for APAS® Independence across the pharmaceutical manufacturing market in the United States, Canada and Singapore. PSC Biotech are leaders in the provision of consulting services to pharmaceutical companies, with over 500 employees globally. The appointment of PSC Biotech allows CCS to leverage PSC Biotech's sales reach and trusted customer relationships to expand its sales and marketing efforts, without requiring CCS to build a large and independent sales organisation.

Under the agreement, PSC Biotech will identify and qualify new sales opportunities. Qualified sales opportunities will be referred to CCS to close, and PSC Biotech will receive a commission payment for all successfully completed sales. All ongoing software and service fees will remain with CCS.

As part of the agreement PSC Biotech has committed to purchase an APAS® Independence instrument for use at the CDMO facility, Biotechnique in York, Pennsylvania. This will be qualified for routine use but will also be used to establish a centre of excellence for the APAS® technology in the United States.

An Investor Presentation was completed following the appointment. To listen to a recording of the call, please use the following link: [Investor presentation with PSC Biotech, CEO and Founder, John Clapham](#)

Financial & Corporate

Investor Customer Insights Series

Ahead of the Company's upcoming AGM, CCS has hosted an Investor Customer Insight Series with presentations from AstraZeneca's Head of Microbiology, Science & Technology | Global Product Development, Karen Capper and CSL's Global Head of QC Technical Services, Craig Stephens. Presenters spoke about their experience with the APAS® Independence technology and their vision of deployment throughout their companies. A five-minute video highlight summary can be viewed online: https://youtu.be/-O9m0AC_-fk?si=rIBSBYugV7oZRqLf and the full versions of these presentations are also available on our investor section of the Company website: <https://www.cleverculturesystems.com/investors/investor-centre>.

Financial stability maintained – \$1.4 million cash balance together with \$3.9 million in expected or committed cash inflows expected over the next two quarters.

The Company remains in a manageable financial position underpinned by \$1.4 million in cash at 30 September 2026, together with expected cash inflows of at least \$3.9 million in the next two quarters, comprising:

- \$1.9 million in receivables at 30 September 2026, of which \$0.7 million has been subsequently received in October; and
- \$2.0 million in committed and expected inflows from customers, including those in an advanced stage of contract finalisation (refer Outlook section).

Approximately \$2.0 million of these expected inflows are expected to be received in the next quarter, ended 31 December 2026.

For the Quarter, the Company reported total net cash outflows of \$0.3 million, represented by:

- Net cash outflows from Operating and Investing activities of \$0.3 million, which included:
 - \$1.5 million in cash inflows from customers;
 - \$0.8 million received for the Company's FY26 Research & Development Tax Incentive claim; and
 - \$2.6 million in cash outflows from expenditures comprising our usual quarterly cost base of \$1.6 million, together with \$1.0 million related to the replenishment of parts inventory, direct sales related costs (manufacturing, installation and shipping) and a small increase in corporate costs as is usual following financial year end.
- Net cash inflows from Financing activities were less than \$0.1 million.

On 30 June 2026, the Company entered into a number of unsecured loan agreements as a capital efficient means of funding short-term working capital requirements, including inventory purchasing to meet expected future sales demands and the working capital impact of alternative customer acquisition models, including instrument leasing. These loans, totalling \$1.7 million, are due for repayment on 31 December 2026, inclusive of interest.

To maintain a prudent cash balance while supporting the anticipated step-change in sales during FY27, the Company expects to extend the existing loan facilities by up to 12 months, under broadly similar terms. This provides a non-dilutive and capital-efficient approach to managing working capital requirements, preserving cash to support increased sales activity while minimising dilution for shareholders. The ability to pursue this approach reflects the Company's improved commercialisation progress and positive sales performance expectations, which provide greater confidence in the outlook for future revenue.

Cashflows for the Quarter include related party payments of \$175,000 to Directors, comprising the Managing Director's salary and Non-Executive Directors' fees.

Outlook

Sales outlook expected to deliver a strong finish to H1 FY27

Following the end of the Quarter, the Company has worked closely with existing and new customers to advance a number of sales opportunities.

The Company is in final procurement discussions with two existing global pharmaceutical customers as they complete their evaluations of APAS® Independence. These expected sales have the potential to establish an important milestone to create further opportunities for additional sales across two global networks. Purchase orders are expected during Q2 FY27, which are also expected to be invoiced within that quarter.

The Company is also in the final stage of finalising a purchase commitment from a new single-site pharmaceutical manufacturer, with installation and qualification being planned before the end of the 2026 calendar year. The sales opportunity originated at the APAS® discovery day, held at AstraZeneca in June 2026 and has since progressed through the sales process, demonstrating the value of customer-led demonstrations in advancing commercial opportunities.

If these recent developments progress as expected, the resulting sales and evaluations would reach 8 units for the first half of FY27, matching the full-year FY26 sales, and would set the foundation for a potential step change for the full-year FY27 sales outlook.

For further information on these recent developments, refer to ASX Announcement dated 28 October 2026.

APAS® Independence presented at major conferences in Australia, Europe and United States

October and November represent the most significant period for the Company for presentation of the APAS® technology at conferences and global events. The Company has presented at the **PDA APAC Aseptic Manufacturing Excellence Conference** and **EDQM Microbiology Symposium** events held in Australia and France respectively. Over the coming weeks, there will be further presentations featuring APAS® Independence at the **PDA Microbiology Conference** in the United States and by AstraZeneca at the **Pharmalab Congress** in Germany.

These conferences are a key platform to establish the APAS® Independence as a leading technology for environmental monitoring and serve to build trust with potential customers. As artificial intelligence technologies are becoming established within the pharmaceutical industry, the questions relating to APAS® have shifted to understand how the system meets the stringent requirements of GMP for validation and performance. CCS continue to lead the way in the field and the Company's scientific approach to technology validation remains a key differentiator in the market. Along with the presentations, Clever Culture Systems have a booth presence and host private in-person events to advance sales opportunities and generate new customer leads.

Company AGM

The Company will hold its 2026 Annual General Meeting on **Tuesday, 17 November 2026 at 11.00am (ACDT)**. The meeting will be an in-person event at **the offices of CCS, 16 Anster Street, Adelaide, South Australia**. Following the AGM, the Company will host a Technology Showcase Event.

In addition, for those shareholders unable to attend in person, you will be able to observe the meeting remotely via the following Zoom link: [Clever Culture Systems Company AGM](#)

You must register prior to the event to be able to access the webinar. Once registered you will be sent the details for joining the webinar, including a calendar invitation. Please note that while the Zoom link will allow you to observe the meeting proceedings, it will not provide a platform for participation.

Approved for release by the CCS Board.

– ENDS –

About Clever Culture Systems

Clever Culture Systems (CCS) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology is the only US FDA-cleared artificial intelligence technology for automated culture plate reading. The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

Clever Culture Systems
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@cleverculturesystems.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Clever Culture Systems Ltd

ABN

95 107 670 673

Quarter ended ("current quarter")

September 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	1,486	1,486
1.2 Payments for		
(a) research and development	(39)	(39)
(b) operating costs & manufacturing	(1,240)	(1,140)
(c) advertising and marketing	(37)	(37)
(d) short term leases		
(e) staff costs	(1,002)	(1,002)
(f) administration and corporate costs	(246)	(246)
1.3 Dividends received (see note 3)		
1.4 Interest received	2	2
1.5 Interest and other costs of finance paid	(11)	(11)
1.6 Income taxes paid		
1.7 Government grants and tax incentives	770	770
1.8 Other		
1.9 Net cash from / (used in) operating activities	(317)	(317)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities		
(b) businesses		
(c) property, plant and equipment	(12)	(12)
(d) investments		
(e) intellectual property	-	-
(f) other non-current assets		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	Net cash from / (used in) investing activities	(12)	(12)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities		
3.5	Proceeds from borrowings	100	100
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid		
3.9	Other (Repayment of lease principal)	(63)	(63)
	Other (Repayment of share placement facility)		
3.10	Net cash from / (used in) financing activities	37	37

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	1,697	1,697
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(317)	(317)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(12)	(12)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	37	37
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	1,405	1,405

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,325	1,617
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (term deposits)	80	80
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,405	1,687

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(175)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

Item 6.1 relates to Cash remuneration paid to the Directors, including remuneration paid to the Managing Director.

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	1,600	1,600
7.2	Credit standby arrangements	50	26
7.3	Other (please specify)		
7.4	Total financing facilities	1,650	1,626
7.5	Unused financing facilities available at quarter end		24
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	<p><u>Item 7.1</u> On 30 June 2026, the Company entered into a number of loan agreements to provide total funding of \$1,600,000 to assist with short term working capital requirements. Loan proceeds of \$1,500,000 were received during the quarter ended 30 June 2026, with the remaining \$100,000 received on 1 July 2026. The loans are unsecured.</p> <p>An amount of \$1,680,000 is due for repayment on 31 December 2026, including interest of \$80,000.</p> <p><u>Item 7.2</u> is a corporate credit card facility which is paid off in full each month.</p>		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(317)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,405
8.3	Unused finance facilities available at quarter end (item 7.5)	24
8.4	Total available funding (item 8.2 + item 8.3)	1,429
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	4.5
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
	8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer:	
	8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer:	

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 October 2026

Authorised by: the Board of Directors
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.